In patients with HCV-related advanced cirrhosis, the effects of SVR by DAAs on decompensation and liver deaths is less clearcut, since up to 30 % of patients do not improve, and no predictors of outcome have been identified. We used 13 C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis.
Aminopyrine Breath Test Predict Liver-related Events and Death in HCV-related Cirrhosis on SVR after DAA Therapy
Giannini, Edoardo G;
2020-01-01
Abstract
In patients with HCV-related advanced cirrhosis, the effects of SVR by DAAs on decompensation and liver deaths is less clearcut, since up to 30 % of patients do not improve, and no predictors of outcome have been identified. We used 13 C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Liver Int & ABT in HCV following DAAs.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
654.05 kB
Formato
Adobe PDF
|
654.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
